Executive Summary:
- QQ1 2025 activity for Anixa Biosciences shows no reported revenue with a quarterly operating loss of $3.386 million and a net loss of $3.184 million. R&D expenditure totaled $1.552 million and G&A expense was $1.834 million, driving the overall expense base in the quarter. Earnings per share stood at -$0.099 on a diluted basis (weighted-average shares ≈ 32.197 million).
- The company ended the period with a robust liquidity cushion: cash and cash equivalents of $1.053 million and $16.202 million in short-term investments, bringing total liquid assets to roughly $17.255 million. The current ratio is an unusually high 9.35x, reflecting a conservative balance sheet with limited near-term payables relative to liquid assets. Net debt is negative, underscoring a liquidity-friendly position given the small debt load ($230k total debt; long-term debt of $194k).
- Cash used in operating activities was $2.904 million for QQ1 2025, with net cash used for investing activities of $2.703 million and financing activities consuming $0.017 million. Free cash flow for the quarter was -$2.904 million, implying annualized cash burn in the low $11–12 million range barring any material revenue or milestone inflows.
- The quarter reinforces Anixa’s status as a pre-revenue biotech with a pipeline anchored in oncology and infectious disease programs, including chimeric receptor T cell therapies, ovarian cancer targets, and antiviral vaccine/drug candidates. A MolGenie GmbH collaboration to discover antiviral candidates remains a notable external partnership capability.
- Looking ahead, no formal forward guidance is provided in the data. Catalysts will likely arise from clinical trial progress, partnership announcements, and any data readouts across the oncology vaccine/therapeutics and antiviral programs. The investment thesis hinges on successful pipeline advancement, potential collaborations, and the ability to extend the current liquidity runway while managing burn.